Get the Stockscreener App
4.38
6.61%
-0.31
After Hours:
4.40
0.02
+0.46%
Sionna Therapeutics Inc stock is traded at $4.38, with a volume of 790.32K.
It is down -6.61% in the last 24 hours and down -44.20% over the past month.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
See More
Previous Close:
$4.69
Open:
$4.69
24h Volume:
790.32K
Relative Volume:
0.82
Market Cap:
$198.03M
Revenue:
Net Income/Loss:
$-85.57M
P/E Ratio:
-2.2853
EPS:
-1.9166
Net Cash Flow:
$-72.14M
1W Performance:
-7.79%
1M Performance:
-44.20%
6M Performance:
-89.51%
1Y Performance:
-85.06%
1-Day Range:
$4.365
$4.795
1-Week Range:
$4.365
$5.12
52-Week Range:
$4.01
$54.97
Sionna Therapeutics Inc Stock (SION) Company Profile
Name
Sionna Therapeutics Inc
Sector
Industry
Phone
617-819-2020
Address
21 HICKORY DRIVE, SUITE 500, WALTHAM
Compare SION vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
4.38 | 198.03M | 0 | -85.57M | -72.14M | -1.9166 |
VRTX
Vertex Pharmaceuticals Inc
|
485.22 | 122.98B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
216.25 | 86.33B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
753.12 | 77.54B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
802.64 | 50.47B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.44 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sionna Therapeutics Inc Stock (SION) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-26 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-10-26 | Downgrade | Citizens | Mkt Outperform → Mkt Perform |
| Aug-10-26 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-10-26 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Aug-10-26 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Aug-10-26 | Downgrade | Stifel | Buy → Hold |
| Aug-10-26 | Downgrade | Wedbush | Outperform → Neutral |
| May-05-26 | Initiated | Wedbush | Outperform |
| Feb-24-26 | Initiated | Citizens | Mkt Outperform |
| Dec-01-25 | Downgrade | RBC Capital Mkts | Sector Perform → Underperform |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-03-25 | Initiated | RBC Capital Mkts | Sector Perform |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-04-25 | Initiated | Guggenheim | Buy |
| Mar-04-25 | Initiated | Stifel | Buy |
| Mar-04-25 | Initiated | TD Cowen | Buy |
View All
Sionna Therapeutics Inc Stock (SION) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - GlobeNewswire Inc.
Ra Capital Management sells $21.8m in Sionna Therapeutics shares By Investing.com - Investing.com Nigeria
Ra Capital Management sells $21.8m in Sionna Therapeutics shares By Investing.com - Investing.com Canada
RA Capital’s Sionna (NASDAQ: SION) stock sale wasn’t under a preset trading plan - Stock Titan
Sionna Therapeutics (Nasdaq:SION)Stock Analysis - Simply Wall Street
Ra Capital Management sells $21.8m in Sionna Therapeutics shares - Investing.com
Sionna Therapeutics CMO Charlotte McKee Granted RSUs and Stock Option Repricing Announced - Kalkine Media
Sionna (SION) cuts CFO option price to $7.18 - Stock Titan
Sionna Therapeutics (SION) cuts CLO's option price and adds new RSUs - Stock Titan
Sionna Therapeutics (SION) cuts CEO option exercise price - Stock Titan
Sionna Therapeutics, Inc. (SION) Stock Analysis: Unpacking a 192% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Sionna (SION) cuts nearly half its jobs to back one cystic fibrosis program - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - FinancialContent
Sionna Therapeutics faces securities fraud prob... - Pluang
SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Sionna Therapeutics - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Sionna Therapeutics, Inc. (SION) And Encourages Shareholders to Reach Out - ACCESS Newswire
SION INVESTIGATION: Investigation Launched into Sionna - GlobeNewswire
Sionna Therapeutics stock plunges 91% after fai... - Pluang
Securities Fraud Investigation Into Sionna Therapeutics, - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc.SION - financialcontent.com
Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations - GlobeNewswire
Securities Fraud Investigation Into Sionna Therapeutics, - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sionna Therapeutics, Inc. (SION) And Encourages Stockholders to Connect - ACCESS Newswire
Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Sionna (SION) Earnings Reading: Profit Per Share Clears Its Benchmark in the Latest Reading; Price Move - vinanet.vn
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - Yahoo Finance
Vertex Pharmaceuticals' Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead - The Motley Fool
2026-08-20 | Sionna Therapeutics, Inc. (SION) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | NDAQ:SION | Press Release - Stockhouse
Sionna (SION) Quarterly Figures: The Bottom-Line Figure Beats Its Comparison in the Current Update; Trading Response: The Share Price Adds 5.22% for the Current SessionTangible Book Value - vinanet.vn
Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sionna Therapeutics, Inc. (SION) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Sionna shares plunge 92% after Phase 2a trial o... - Pluang
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Sionna Therapeutics (SION) Securities Investigation NoticeLevi & Korsinsky - PR Newswire
Investigation Launched into Sionna Therapeutics, Inc. (SION), Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - Business Wire
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - WBOC TV
Securities Fraud Investigation Into Sionna Therapeutics, Inc. (SION) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz - FinancialContent
Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information - Business Wire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Sionna Therapeutics (SION) - GlobeNewswire
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - The AI Journal
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - lincolnjournal.com
SION INVESTOR ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - The Daily Tribune News
SION Investors Have Opportunity to Join Sionna Therapeutics, Inc. Fraud Investigation with SBS Law - Business Wire
symbol__ Stock Quote Price and Forecast - CNN
Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
SION Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Sionna Therapeutics (SION) - Business Wire
SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - PR Newswire
Sionna Therapeutics (SION) Resets After Trial Miss, Is The Discount Now Too Deep? - Yahoo Finance
Sionna Therapeutics Inc Stock (SION) Financials Data
Revenue
Net Income
Cash Flow
EPS
Sionna Therapeutics Inc Stock (SION) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA Capital Healthcare Fund, L. | Director |
Sep 17 '26 |
Proposed Sale |
6.33 |
3,448,811 |
21,834,318 |
0 |
| ORBIMED ADVISORS LLC | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Thompson Peter A. | Director |
Jul 07 '26 |
Sale |
44.86 |
85,918 |
3,854,281 |
2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Sale |
43.60 |
10,250 |
446,862 |
0 |
| Fitzpatrick Jennifer | Chief Legal Officer |
Jul 06 '26 |
Option Exercise |
6.11 |
10,250 |
62,628 |
10,250 |
| JENNIFER FITZPATRICK | Officer |
Jul 06 '26 |
Proposed Sale |
43.99 |
10,250 |
450,898 |
0 |
| ORBIMED ADVISORS LLC | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| Thompson Peter A. | Director |
Jun 30 '26 |
Sale |
45.50 |
115,844 |
5,270,902 |
2,555,877 |
| OrbiMed Private Investments VI | Shareholder |
May 29 '26 |
Proposed Sale |
42.80 |
1,082,480 |
46,330,144 |
0 |
| Thompson Peter A. | Director |
May 27 '26 |
Sale |
44.49 |
101 |
4,493 |
2,671,721 |
4.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):